Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

May 14, 2024

BUY
$0.19 - $0.36 $57,889 - $109,686
304,684 New
304,684 $61,000
Q2 2022

Aug 15, 2022

BUY
$0.19 - $0.36 $57,889 - $109,686
304,684 New
304,684 $61,000

Others Institutions Holding ITRM

About Iterum Therapeutics plc


  • Ticker ITRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,233,400
  • Market Cap $14.1M
  • Description
  • Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract inf...
More about ITRM
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.